BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 19461083)

  • 1. Protein expression of carcinoembryonic antigen cell adhesion molecules in benign and malignant melanocytic skin lesions.
    Gambichler T; Grothe S; Rotterdam S; Altmeyer P; Kreuter A
    Am J Clin Pathol; 2009 Jun; 131(6):782-7. PubMed ID: 19461083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minichromosome maintenance proteins are useful adjuncts to differentiate between benign and malignant melanocytic skin lesions.
    Gambichler T; Shtern M; Rotterdam S; Bechara FG; Stücker M; Altmeyer P; Kreuter A
    J Am Acad Dermatol; 2009 May; 60(5):808-13. PubMed ID: 19389522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of microtubule-associated protein 2 in melanocytic skin lesions.
    Gambichler T; Rotterdam S; Radkowski K; Altmeyer P; Kreuter A
    Am J Clin Pathol; 2009 May; 131(5):710-4. PubMed ID: 19369632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Versican overexpression in cutaneous malignant melanoma.
    Gambichler T; Kreuter A; Grothe S; Altmeyer P; Brockmeyer NH; Rotterdam S
    Eur J Med Res; 2008 Nov; 13(11):500-4. PubMed ID: 19073385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A subgroup of melanocytic nevi on the distal lower extremity (ankle) shares features of acral nevi, dysplastic nevi, and melanoma in situ: a potential misdiagnosis of melanoma in situ.
    Khalifeh I; Taraif S; Reed JA; Lazar AF; Diwan AH; Prieto VG
    Am J Surg Pathol; 2007 Jul; 31(7):1130-6. PubMed ID: 17592281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression.
    Einspahr JG; Thomas TL; Saboda K; Nickolof BJ; Warneke J; Curiel-Lewandrowski C; Ranger-Moore J; Duckett L; Bangert J; Fruehauf JP; Alberts DS
    Cancer; 2007 Dec; 110(11):2519-27. PubMed ID: 17932890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleolin protein expression in cutaneous melanocytic lesions.
    Mourmouras V; Cevenini G; Cosci E; Epistolato MC; Biagioli M; Barbagli L; Luzi P; Mannucci S; Miracco C
    J Cutan Pathol; 2009 Jun; 36(6):637-46. PubMed ID: 19515042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of claudin-1 expression in tumor-associated vessels correlates with acquisition of metastatic phenotype in melanocytic neoplasms.
    Cohn ML; Goncharuk VN; Diwan AH; Zhang PS; Shen SS; Prieto VG
    J Cutan Pathol; 2005 Sep; 32(8):533-6. PubMed ID: 16115050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
    Boyd AS; Shakhtour B; Shyr Y
    J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
    Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
    J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular analysis of melanoma precursor lesions.
    Wang Y; Rao U; Mascari R; Richards TJ; Panson AJ; Edington HD; Shipe-Spotloe JM; Donnelly SS; Kirkwood JM; Becker D
    Cell Growth Differ; 1996 Dec; 7(12):1733-40. PubMed ID: 8959342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of cytoplasmic p27 expression in human melanoma.
    Chen G; Cheng Y; Zhang Z; Martinka M; Li G
    Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2212-21. PubMed ID: 21828232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) in posterior uveal melanoma: correlation with clinical and histological survival markers.
    Khatib N; Pe'er J; Ortenberg R; Schachter J; Frenkel S; Markel G; Amer R
    Invest Ophthalmol Vis Sci; 2011 Dec; 52(13):9368-72. PubMed ID: 22039239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin D1 expression in melanocytic lesions of the skin.
    Ramirez JA; Guitart J; Rao MS; Diaz LK
    Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
    Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
    Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of heat shock protein 105 and 70 in malignant melanoma and benign melanocytic nevi.
    Park HS; Park CH; Choi BR; Lim MS; Heo SH; Kim CH; Kang SG; Whang KU; Cho MK
    J Cutan Pathol; 2009 May; 36(5):511-6. PubMed ID: 19476517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TSLC1 expression discriminates cutaneous melanomas from dysplastic nevi.
    You Y; Wang SH; Zhang JF; Zheng SY
    Melanoma Res; 2012 Dec; 22(6):430-5. PubMed ID: 23047161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. bcl-2 protein expression in melanocytic neoplasms of the skin.
    Ramsay JA; From L; Kahn HJ
    Mod Pathol; 1995 Feb; 8(2):150-4. PubMed ID: 7777475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Markers of melanocytic tumour progression.
    Ruiter DJ; van Muijen GN
    J Pathol; 1998 Dec; 186(4):340-2. PubMed ID: 10209480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.